- Home
- NEGG vs MOLN Comparison
NEGG vs MOLN Comparison
Compare NEGG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEGG | MOLN |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Switzerland |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.3M | 170.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEGG | MOLN |
|---|---|---|
| Price | $12.70 | $3.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 41.6K | 1.5K |
| Earning Date | 08-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $3.53 |
| 52 Week High | $96.29 | $5.36 |
Technical Indicators
Market Signals| Indicator | NEGG | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 44.22 |
| Support Level | $12.52 | $3.79 |
| Resistance Level | $14.98 | $4.39 |
| Average True Range (ATR) | 0.71 | 0.13 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 14.44 | 16.49 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.